GD Topic - Monkeypox Outbreak: A Wake-Up Call for Better Disease Surveillance

9 mins read20 Views Comment

Senior Executive - Editorial

Updated on Sep 26, 2025 15:44 IST

Candidates planning to pursue MBA must prepare for the Group Discussion Round as it can make or take the chances of admission. Check out the article below for a discussion on the GD topic: Monkeypox outbreak. Learn about the disease, its symptoms, the 2022-24 outbreak, and its current status.

In the competitive world of MBA admissions, the Group Discussion (GD) round holds the answer. Apart from the numbers achieved in MBA entrance exams like CAT, XAT, SNAP, NMAT, and MAH MBA CET, the GD round evaluates candidates on essential skills such as communication, leadership, confidence, analytical thinking, and time management. GD is conducted to identify individuals who can effectively collaborate, persuade, and present their viewpoints. These are the basic traits that every top B-school values in its future managers.

Read the below article for a discussion on one of the important current GD topics: the Monkeypox Outbreak.

Check Out: Top MBA Colleges in India

Table of content

What is Monkeypox?
Types of Mpox (Monkeypox)
Signs and Symptoms of Monkeypox
2022-2024 Monkeypox Outbreak
Current Situation of Monkeypox
Monkeypox Cases: Statistics
Top GD Topics for MBA Admission Process

What is Monkeypox?

Mpox or Monkeypox is a rare viral disease caused by the monkeypox virus, a member of the Orthopoxvirus genus in the Poxviridae family. Mpox is closely related to smallpox, but it is less sever and generally less contagious. It is a zoonotic disease, which means that the disease spreads from animals to humans. However, Mpox can also spread from human to human. Monkeypox is considered an emerging infectious disease and has gained global attention in recent years due to its outbreak outside its usual endemic regions.

Monkeypox was first identified in 1958 in monkeys kept for research and this how the disease got its name. However, monkeys are not the primary carriers of the virus. It is primarily found in certain rodents, such as squirrels and rats, which serve as the natural hosts. The first human case of monkeypox was recorded in 1970 in the Democratic Republic of Congo (DRC). A child was diagnosed with monkeypox when the world was trying to eradicate smallpox. Since then, monkeypox has been endemic to certain parts of Central and West Africa, particularly in countries like Nigeria, Cameroon, and the DRC.

Types of Mpox (Monkeypox)

The monkeypox virus (Mpox or MPXV) has two primary genetic clades, Clade I and Clade II. These are divided into sub-clades. The clades are separated based on their geographic origins, severity, and transmission characteristics.

Clade I (Central African Clade):

Clade Ia is found in endemic areas within the Democratic Republic of Congo (DRC). Clade Ia transmits more efficiently through human-to-human contact compared to other clades and involves a high risk. It is due to severe disease symptoms and 6-10% mortality rates.
Clade Ib affects non-endemic regions in the DRC and neighboring countries. It is also classified as high-risk. The Clade Ib caused an increase in cases due to emerging networks of transmission, including sexual contact.

Clade II (West African Clade)

Clade IIa: This subclade is found in endemic regions such as Nigeria and other West and Central African countries, and causes milder disease symptoms compared to Clade I. The mortality rate of Clade IIa is lower; 1-3%. Also, its transmission is less efficient compared to Clade I.
Clade IIb: This subclade is seen outside endemic regions, especially in non-endemic countries in Europe, Asia, and the Americas. It is considered as moderately risky and has been seen during 2022 and 2024 outbreaks. The cause of its transmission is human-to-human close physical or sexual contact.

Signs and Symptoms of Monkeypox

Monkeypox symptoms usually appear within 1 to 21 days after exposure to the virus. This period is known as the incubation period. The illness typically lasts for 2 to 4 weeks. These symptoms can range from mild to severe. It depends on the individual’s health and the strain of the virus.

Common Symptoms of Mpox:

Rash
Fever
Sore Throat
Headache
Muscle Aches
Back Pain
Low Energy
Swollen Lymph Nodes

For some people, rash is the first symptom. For others, it may be fever, muscle ache, or a sore throat.

Mpox Rash

The mpox rash can begin on the face and then spread to other parts of the body, such as the palms of the hands, soles of the feet, and groin. It may even start in areas where the contact occurred, such as the genital areas.

It spreads in the following stages:

Flat sores (macules): Small, red spots on the skin.
Raised bumps (papules): The sores become elevated.
Blisters (vesicles): Fluid-filled bumps that may itch or cause discomfort.
Pus-filled lesions (pustules): The blisters become filled with yellowish pus.
Crusting and healing: The lesions dry up, scab over, and eventually fall off. This leaves a new layer of skin underneath.

The number of lesions can vary between individuals. Some people may have just a few sores, while others may develop hundreds. These lesions can appear anywhere, including:

Face, mouth, and throat
Palms of the hands and soles of the feet
Groin and genitals
Anus

Severe Symptoms and Complications

Painful swelling of the rectum (proctitis) or difficulty urinating (dysuria).
Bacterial skin infections may result in abscesses or permanent skin damage.
Respiratory issues, including pneumonia or difficulty breathing.
Eye infections (keratitis or corneal infection) may result in vision loss.
Digestive problems like vomiting and diarrhea. It causes dehydration or malnutrition.
Serious infections, including sepsis, brain inflammation (encephalitis), heart inflammation (myocarditis), and infections of the urinary or genital organs.

High-Risk Groups

Individuals who are at a higher risk of severe illness or death from monkeypox, include:

Children
Pregnant Women
People with weak Immune System (such as those living with uncontrolled HIV or undergoing treatments that suppress immunity)

2022-2024 Monkeypox Outbreak

The monkeypox outbreak 2022 was the first large-scale spread of the disease. It spread from outside its usual endemic regions (Central and West Africa) to non-endemic countries across Europe, North America, South America, Asia, and the Middle East.

The first case of the 2022 outbreak was reported in the United Kingdom in May. By August 2022, over 14,000 laboratory-confirmed cases were reported globally, signaling the start of a global health concern. In India, the first monkeypox case was detected on July 14, 2022. It was detected when a traveler from the UAE, who had returned to Kerala, started developing symptoms. This marked India's entry into the global outbreak, with subsequent cases being reported in various states. The cases were found particularly among individuals with a history of international travel.

Earlier, monkeypox spread through animal-to-human transmission in forested areas. However, in 2022, monkeypox spread through human-to-human contact. People were affected through close contact with infected individuals, respiratory droplets, or contaminated objects. This was due to an increase in international travel and social meets.

As cases increased worldwide, the World Health Organization (WHO) declared monkeypox a Public Health Emergency of International Concern (PHEIC) in July 2022. With PHEIC, the World Health Organization emphasized the urgent need for coordinated global action. The Indian government also increased its surveillance, issued guidelines for healthcare facilities, and educated people about the symptoms and preventive measures of monkeypox. By May 2023, when WHO saw a decline the global cases, it declared the PHEIC over.

Monkeypox has been reported for more than a decade in the DRC. Also, the number of reported cases has increased every year. In 2023, the number of reported cases increased significantly. By mid-August 2024, the number exceeded the previous year’s total cases by more than 15,600 cases and 537 deaths. Due to the emergence and rapid spread of a new virus strain, clade 1b through sexual networks in DRC and its detection in its neighboring countries, on 14 August 2024, the World Health Organization (WHO) Director-General declared monkeypox a Public Health Emergency of International Concern (PHEIC) under the International Health Regulations (2005).

At the time, the World Health Organization (WHO) was actively working to ensure equitable access to vaccines for mpox, particularly in lower-income countries that have not yet issued their own national regulatory approvals. Two vaccines were in use on the WHO’s Strategic Advisory Group of Experts on Immunization recommendation. WHO-listed national regulatory authorities and individual countries also approved these vaccines.

To speed up vaccine access, the Director-General of the WHO also initiated Emergency Use Listing (EUL). It allowed faster approval and procurement by global partners such as Gavi and UNICEF. In addition, WHO coordinated efforts with vaccine manufacturers and partners through the interim Medical Countermeasures Network to ensure the equitable distribution of vaccines, therapeutics, diagnostics, and other critical tools. Since then, WHO has been working with affected countries and partners to control these outbreaks.

Current Situation of Monkeypox

In November 2024, WHO conducted the latest global mpox rapid risk assessment. According to the report, the risk of monkeypox was assessed as follows:

Clade Ib MPXV is affecting non-endemic areas, including the Democratic Republic of the Congo (DRC) and neighboring countries. It is considered to pose a high risk.
Clade Ia MPXV is primarily circulating in endemic regions within the DRC. It is also categorized as high-risk.
Clade II MPXV is observed in countries such as Nigeria and other areas in West and Central Africa. It is assessed to present a moderate risk.
Clade IIb MPXV is associated with the ongoing global mpox epidemic. It is also deemed to have a moderate risk.

Monkeypox Cases: Statistics

As per the data reported to WHO by November 30, 2024; since January 1, 2022, 127 member states across all 6 WHO regions have reported cases of mpox to WHO. Additionally, 117,663 laboratory-confirmed cases and 2 probable cases, including 263 deaths have been reported to WHO. As of November 2024, compared to the number of reported monthly cases in October, the number of cases in November has decreased by 13.2%.

The 10 most affected countries globally since January 1, 2022, till November 2024 include:

United States of America (34,349 cases)
Brazil (13,236 cases)
Democratic Republic of the Congo (10,492 cases)
Spain (8,443 cases)
France (4,371 cases)
Colombia (4,280 cases)
Mexico (4,192 cases)
The United Kingdom (4,146 cases)
Germany (4,040 cases)
Peru (3,949 cases)

These countries collectively constitute 77.8% of the total cases reported globally.

Check Out Total Mpox cases by WHO region from 1 Jan 2022, as of 30 Nov 2024 at WHO’s official website

From 2024, as of January 12, 2025, 21 countries have reported 15,094 confirmed cases, including 64 deaths to WHO. The three countries with the most number of cases from 2024 include the Democratic Republic of the Congo (DRC) with 9513 cases, Burundi with 3116 cases, and Uganda with 1,830 cases.